Canadian Drugmaker Apotex Seeks Up to $730 Million in First-Half IPO

Canadian generic drug manufacturer Apotex Inc. is looking at the first half of the year for an initial public offering in Toronto that could raise as much as C$1 billion ($730 million), according to people familiar with the matter.

An IPO of that size would be Canada’s largest debut since 2021. RBC Capital Markets, Jefferies Financial Group and TD Securities are advising on the transaction, people familiar with the offering have said.